Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:54:02.711Z.
Calculation as of: 2026-10-06T19:54:02.711Z.
Quote observation: 2026-10-06T19:50:44.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8cea65d131d106392be27e1d05384ba8473c5e5a591a362ec8848616303db7fd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$204.99M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$200.09M
EV/EBITDA Ratio
N/A
TTM Avg
5.75x
3Y Avg
5.75x
5Y Avg
5.75x
Market Cap
$206.72M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$208.17M
EV/EBITDA Ratio
15.16x
TTM Avg
13.21x
3Y Avg
12.70x
5Y Avg
13.38x
Market Cap
$210.64M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Surrozen, Inc. (SRZN) | $202.49M | N/A | N/A | N/A | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $204.99M | N/A | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $200.09M | N/A | 5.75x | 5.75x | 5.75x |
| Exagen Inc. (XGN)vs › | $199.08M | N/A | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $206.72M | N/A | N/A | N/A | N/A |
| Alector, Inc. (ALEC)vs › | $199.29M | N/A | 16.55x | 16.55x | 16.55x |
| Pro-Dex, Inc. (PDEX)vs › | $208.17M | 15.16x | 13.21x | 12.70x | 13.38x |
| Sionna Therapeutics, Inc. (SION)vs › | $210.64M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $210.38M | N/A | 6.24x | 9.83x | 9.83x |
| Entrada Therapeutics, Inc. (TRDA)vs › | $209.44M | N/A | 14.91x | 15.90x | 15.90x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
